The Matthew Larson Foundation for Pediatric Brain Tumors (aka IronMatt) seeks to fund basic and translational science projects and family education in Pediatric Brain Tumor Research. To be considered for the 2025 awards, applicants must submit a Letter of Intent by November 17, 2024. No extensions on that timeframe will be granted.
Please see the requirements for the Letter of Intent. Successful applicants will be invited to submit a formal application after the Letter of Intent is reviewed.
All Letters of Intent and Applications must demonstrate relevance to the purpose of the fund.
The Foundation uses a peer-reviewed process to identify the merit of proposed projects. The Medical Advisory Committee serves as the review committee and acts in an advisory capacity to the Board.
All decisions of the Board are final and not subject to appeal. All applicants will be notified of final decisions. The Foundation is under no obligation to give comments about applications not funded.
The Primary Investigator on the application must be an MD or PhD at a not-for-profit, medical or scientific institution and must hold an academic rank of assistant professor (or equivalent) or instructor (or equivalent.) Investigators at multiple institutions are invited to submit joint applications as long as both institutions give permission and agree to abide by all Foundation requirements.
Applicants may apply for one of the two level of grants that are offered:
- Grant not to exceed $100,000 over a one year period
- Grant not to exceed $150,000 per year over a three year period for longer-term projects
Acknowledgement is required for all grants in any subsequent reports or publications.
- For the $100,000 grant, final grant report is required. Dissemination of findings is required (poster, presentation, publication) and plans should be detailed in grant application.
- For the (up to) $450,000 grants, interim reports are required to be provided for review by the Medical Advisory Committee annually each September. Reports must provide detailed information of progress made and are a determinant of continued funding. Final reports, abstracts, posters and publication (submission of manuscript) are required and should be detailed in the grant application.
- Failure to comply with the reporting and acknowledgement requirements of support from The Matthew Larson Foundation will exclude the investigator and the investigator’s institution from future applications to The Matthew Larson Foundation for Pediatric Brain Tumors.
Grants will be announced by April 1, 2025 for a one-year funding period starting May 1, 2025.
Funds may be used for new or existing research projects but all sources of funding for the project, including those pending, must be disclosed to the Foundation. Prior and current funding for the principal investigator must also be disclosed.
Only direct costs will be funded. No indirect or other institutional costs will be funded. Salaries, equipment and supplies will be allowed as long as they are direct costs of the project. Salary support must match percentage effort. Travel funding is specifically excluded.
The funds must be kept segregated from other research funds to ensure accurate and timely financial reporting of the research project.
Funding by The Matthew Larson Foundation for Pediatric Brain Tumors must be acknowledged in all presentations and publications of funded research projects.
Failure to follow these guidelines in their entirety will eliminate the applicant from the process.
IronMatt Research Grants 2024/2025
The Matthew Larson Foundation for Pediatric Brain Tumors (aka IronMatt) seeks to fund basic and translational science projects and family education in Pediatric Brain Tumor Research. To be considered for the 2025 awards, applicants must submit a Letter of Intent by November 17, 2024. No extensions on that timeframe will be granted.
Please see the requirements for the Letter of Intent. Successful applicants will be invited to submit a formal application after the Letter of Intent is reviewed.
All Letters of Intent and Applications must demonstrate relevance to the purpose of the fund.
The Foundation uses a peer-reviewed process to identify the merit of proposed projects. The Medical Advisory Committee serves as the review committee and acts in an advisory capacity to the Board.
All decisions of the Board are final and not subject to appeal. All applicants will be notified of final decisions. The Foundation is under no obligation to give comments about applications not funded.
The Primary Investigator on the application must be an MD or PhD at a not-for-profit, medical or scientific institution and must hold an academic rank of assistant professor (or equivalent) or instructor (or equivalent.) Investigators at multiple institutions are invited to submit joint applications as long as both institutions give permission and agree to abide by all Foundation requirements.
Applicants may apply for one of the two level of grants that are offered:
- Grant not to exceed $100,000 over a one year period
- Grant not to exceed $150,000 per year over a three year period for longer-term projects
Acknowledgement is required for all grants in any subsequent reports or publications.
- For the $100,000 grant, final grant report is required. Dissemination of findings is required (poster, presentation, publication) and plans should be detailed in grant application.
- For the (up to) $450,000 grants, interim reports are required to be provided for review by the Medical Advisory Committee annually each September. Reports must provide detailed information of progress made and are a determinant of continued funding. Final reports, abstracts, posters and publication (submission of manuscript) are required and should be detailed in the grant application.
- Failure to comply with the reporting and acknowledgement requirements of support from The Matthew Larson Foundation will exclude the investigator and the investigator’s institution from future applications to The Matthew Larson Foundation for Pediatric Brain Tumors.
Grants will be announced by April 1, 2025 for a one-year funding period starting May 1, 2025.
Funds may be used for new or existing research projects but all sources of funding for the project, including those pending, must be disclosed to the Foundation. Prior and current funding for the principal investigator must also be disclosed.
Only direct costs will be funded. No indirect or other institutional costs will be funded. Salaries, equipment and supplies will be allowed as long as they are direct costs of the project. Salary support must match percentage effort. Travel funding is specifically excluded.
The funds must be kept segregated from other research funds to ensure accurate and timely financial reporting of the research project.
Funding by The Matthew Larson Foundation for Pediatric Brain Tumors must be acknowledged in all presentations and publications of funded research projects.
Failure to follow these guidelines in their entirety will eliminate the applicant from the process.